Cross-Sector entity
Stepan is most often covered alongside Madrigal Pharmaceuticals, which appears in 2 of these 2 stories. Coverage clusters in earnings, which accounts for 1 of those 2, with the remainder spread across 1 other category. Each carries 5 original sources on average.
2 verified stories tracked
Last mentioned: Feb 24, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Stepan is most often covered alongside Madrigal Pharmaceuticals, which appears in 2 of these 2 stories. Coverage clusters in earnings, which accounts for 1 of those 2, with the remainder spread across 1 other category. Each carries 5 original sources on average. We currently track 2 Cross-Sector stories that mention Stepan, all published on February 24, 2026.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Stepan. Shared-story counts are live from our verified record — not editorial picks.
Patent Extension
Secured Rezdiffra patent protection through 2045.
DGAT-2 and siRNA Expansion
Acquired late-stage DGAT-2 inhibitor and six preclinical siRNA assets.
GLP-1 Acquisition
Madrigal paid $120 million upfront to acquire an oral GLP-1 program.
Rezdiffra Commercial Launch
First full year of Rezdiffra availability in the U.S. market for MASH.
Madrigal Pharmaceuticals reported a transformative 2025, with Rezdiffra net sales reaching $958.4 million during its first full year on the market. The company is aggressively pivoting toward a multi-asset metabolic powerhouse, integrating oral GLP-1 and DGAT-2 programs alongside its core MASH franchise.
The Q4 2025 earnings cycle reveals a retail landscape defined by digital efficiency and premiumization, with Carvana and Freshpet posting double-digit volume growth. Companies are increasingly leveraging loyalty ecosystems and strategic partnerships to drive margins in a stabilizing consumer market.
